“we're ready to launch soon after we receive clearance on that.”

In context

“of the pipeline ideas that you had for diabetes and about their differentiation and timelines, if you can. Geoff Martha: Sure. I will hand that one off to Que. Que Dallara: Yeah, thanks for the question. So, if I start with a recent approval of Simplera Sync in the US, we're ramping that, we're going to be launching that in a limited fashion in the fall. And in Europe, that product has already launched commercially. And just to give you an idea of the volume ramp versus last year, we expect to ramp our volume at least five times what we did last year. So, we have not really begun to see the potential of Simplera on the business yet. Then we have submitted for an ACE pump in iAGC algorithm to FDA in April. So we're ready to launch that, working very well with Abbott to make that happen and we're ready to launch soon after we receive clearance on that. And then -- so that's our CGM option. It's going to address a lot of the Achilles heel of our current CGM lineup. And then we also have a multiple insulin options. We have InPen in market today, our next generation durable pump we expect to submit by the end of this fiscal year and then following, the patch will follow after that. And what you can see in the lineup is significant improvement to our form factor. That's feedback we've been given. And so that makes it more wearable with all these pumps having phone control, which is a feature a lot of our customers have asked for. And then in addition to that, we have our third generation closed-loop algorithm that we believe will be a very exciting development in terms of burden reduction while driving the clinical outcomes that people expe”